Gamma Secretase (EC 3.4.23.) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500
Buy Report View Sample

Published: August 31, 2021 Report Code: GMDGDHC2950TDB-ST

Select Item

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Report Overview

Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer’s disease patients.

The Gamma Secretase (EC 3.4.23.) pipeline drugs market research report provides comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. It also reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development with respective active and dormant or discontinued projects.

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Segmentation by Therapy Areas

The key therapy areas in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are central nervous system, oncology, ear nose throat disorders, non malignant disorders, cardiovascular, genetic disorders, and metabolic disorders. Central nervous system dominates the pipeline market.

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Therapy Areas

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Therapy Areas

For more Gamma Secretase (EC 3.4.23.) pipeline drugs market therapy areas insights, download a free report sample

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are Gamma Secretase Inhibitor, Gamma Secretase Modulator, Presenilin 1 Inhibitor, and Presenilin 1 Activator. Gamma Secretase Inhibitor is the leading mechanism of action in the Gamma Secretase (EC 3.4.23.) pipeline drugs market.

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Mechanisms of Action

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Mechanisms of Action

For more Gamma Secretase (EC 3.4.23.) pipeline drugs market mechanisms of action insights, download a free report sample

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are oral, intravenous, and intratympanic. Most of the drugs are administered through the oral route.

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Routes of Administration

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Routes of Administration

For more Gamma Secretase (EC 3.4.23.) pipeline drugs market routes of administration insights, download a free report sample

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are small molecule, gene therapy, and peptide. Small molecule is the leading molecule type in the Gamma Secretase (EC 3.4.23.) pipeline drugs market.

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Molecule Types

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Molecule Types

For more Gamma Secretase (EC 3.4.23.) pipeline drugs market molecule types insights, download a free report sample

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market – Competitive Landscape

Some of the leading companies in the Gamma Secretase (EC 3.4.23.) pipeline drugs market are Adipo Therapeutics, AlzeCure Pharma AB, Astellas Pharma Inc, Audion Therapeutics BV, Ayala Pharmaceuticals Inc, Eli Lilly and Co, Everfront Biotech Inc, F. Hoffmann-La Roche Ltd, Laminar Pharmaceuticals SA, and Merck & Co Inc. Ayala Pharmaceuticals Inc is the leading company in the pipeline market.

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Companies

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Analysis, by Companies

To know more about the leading players in the Gamma Secretase (EC 3.4.23.) pipeline drugs market, download a free report sample

Gamma Secretase (EC 3.4.23.) Pipeline Drugs Market Report Overview

Key Therapy Areas Central Nervous System, Oncology, Ear Nose Throat Disorders, Non Malignant Disorders, Cardiovascular, Genetic Disorders, and Metabolic Disorders
Key Mechanisms of Action Gamma Secretase Inhibitor, Gamma Secretase Modulator, Presenilin 1 Inhibitor, and Presenilin 1 Activator
Key Routes of Administration Oral, Intravenous, and Intratympanic
Key Molecule Types Small Molecule, Gene Therapy, and Peptide
Leading Companies Adipo Therapeutics, AlzeCure Pharma AB, Astellas Pharma Inc, Audion Therapeutics BV, Ayala Pharmaceuticals Inc, Eli Lilly and Co, Everfront Biotech Inc, F. Hoffmann-La Roche Ltd, Laminar Pharmaceuticals SA, and Merck & Co Inc

Scope

  • The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.).

  • The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.

  • The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects.

  • The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics.

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Adipo Therapeutics LLC
AlzeCure Pharma AB
Astellas Pharma Inc
Audion Therapeutics BV
Ayala Pharmaceuticals Inc
Eli Lilly and Co
Everfront Biotech Inc
F. Hoffmann-La Roche Ltd
Laminar Pharmaceuticals SA
Merck & Co Inc
NeuroGenetic Pharmaceuticals Inc
Pharchoice Therapeutics Inc
Pipeline Therapeutics Inc
SpringWorks Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gamma Secretase (EC

3.4.23.) – Overview

Gamma Secretase (EC

3.4.23.) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Gamma Secretase (EC

3.4.23.) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gamma Secretase (EC

3.4.23.) – Companies Involved in Therapeutics Development

Adipo Therapeutics LLC

AlzeCure Pharma AB

Astellas Pharma Inc

Audion Therapeutics BV

Ayala Pharmaceuticals Inc

Eli Lilly and Co

Everfront Biotech Inc

F. Hoffmann-La Roche Ltd

Laminar Pharmaceuticals SA

Merck & Co Inc

NeuroGenetic Pharmaceuticals Inc

Pharchoice Therapeutics Inc

Pipeline Therapeutics Inc

SpringWorks Therapeutics Inc

Gamma Secretase (EC

3.4.23.) – Drug Profiles

ACD-679 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACD-680 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AL-101 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AL-102 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUD-1001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crenigacestat – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dibenzazepine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EF-005 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate PSEN1 for Heart Failure – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSI-34 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAM-226 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGP-555 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nirogacestat hydrobromide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit PSEN1 for Alzheimer’s Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PIPE-505 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-7185876 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer’s Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Gamma Secretase for Hearing Loss – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PSEN1 for Alzheimer’s Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Modulate Gamma Secretase for Alzheimer’s Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCSD-776890 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gamma Secretase (EC

3.4.23.) – Dormant Products

Gamma Secretase (EC

3.4.23.) – Discontinued Products

Gamma Secretase (EC

3.4.23.) – Product Development Milestones

Featured News & Press Releases

Apr 21, 2021: Ayala Pharmaceuticals announces first patient dosed in phase 1 clinical trial of AL102 in combination with BCMA targeting agent, WVT078, in patients with relapsed/refractory multiple myeloma

Apr 01, 2021: SpringWorks Therapeutics announces dosing of first patient in phase 1b combination study evaluating nirogacestat and Janssen’s BCMA bispecific antibody teclistamab in patients with relapsed or refractory multiple myeloma

Jan 28, 2021: Ayala Pharmaceuticals announces first patient dosed in phase 2 TENACITY clinical trial of AL101 for the treatment of patients with notch-activated triple negative breast cancer

Jan 04, 2021: Ayala Pharmaceuticals to accelerate development of AL102 for the treatment of desmoid tumors in pivotal phase 2/3 study

Sep 18, 2020: Ayala Pharmaceuticals presents positive interim data from phase 2 ACCURACY trial of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma with notch activating mutations at ESMO 2020

Sep 16, 2020: SpringWorks Therapeutics announces collaboration with Children’s Oncology Group to conduct a phase 2 clinical trial of nirogacestat in pediatric patients with desmoid tumors and reports publication of nirogacestat case series in pediatric/young adult desmoid tumor patients

Sep 14, 2020: Ayala Pharmaceuticals to host virtual KOL event reviewing interim data presented at ESMO 2020 from ongoing phase 2 accuracy trial of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma

Jul 27, 2020: Ayala Pharmaceuticals to present updated data from ongoing phase 2 ACCURACY trial of AL101 for the treatment of R/M adenoid cystic carcinoma at the European Society for Medical Oncology (ESMO) virtual congress 2020

Jul 23, 2020: Pipeline Therapeutics initiates Phase 1/2a clinical trial of PIPE-505 in sensorineural hearing loss

Jul 22, 2020: SpringWorks Therapeutics announces full enrollment of phase 3 DeFi trial evaluating nirogacestat in adult patients with desmoid tumors

Jun 22, 2020: SpringWorks Therapeutics announces dosing of first patient in phase 1b combination study evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the treatment of Relapsed or Refractory Multiple Myeloma

Mar 18, 2020: SpringWorks Therapeutics announces issuance of new U.S. composition of matter patent to polymorphic form of Nirogacestat, extending patent protection into 2039

Mar 03, 2020: Ayala Pharmaceuticals granted U.S. FDA Fast Track Designation for AL101 for the treatment of recurrent or metastatic adenoid cystic carcinoma

Dec 09, 2019: Researchers present preclinical data showing synergistic activity of Springworks Therapeutics gamma secretase inhibitor (Nirogacestat) with glaxosmithkline’s BCMA antibody-drug conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH ) Annual Meeting

Sep 30, 2019: Ayala Pharmaceuticals presents encouraging preliminary safety and efficacy data in patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with progressing disease and notch activating mutations from ongoing phase 2 clinical trial at ESMO

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

Gamma Secretase (EC 3.4.23.) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

Most Popular
$7,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Gamma Secretase (EC 3.4.23.) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Other Diseases reports
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Pharmaceuticals
New
Synthetic Biology - Thematic Intelligence
$995 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Gamma Secretase (EC 3.4.23.) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update in real time.

  • Access a live Gamma Secretase (EC 3.4.23.) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more